Cargando…
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes after systemic administration and to antigen-presenting cells after intramuscular injection. However, systemic RNA delivery to non-hepatocytes remains challenging, especially without targeting ligands such as...
Autores principales: | Ni, Huanzhen, Hatit, Marine Z. C., Zhao, Kun, Loughrey, David, Lokugamage, Melissa P., Peck, Hannah E., Cid, Ada Del, Muralidharan, Abinaya, Kim, YongTae, Santangelo, Philip J., Dahlman, James E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376583/ https://www.ncbi.nlm.nih.gov/pubmed/35970837 http://dx.doi.org/10.1038/s41467-022-32281-5 |
Ejemplares similares
-
Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands
por: Gan, Zubao, et al.
Publicado: (2020) -
The Transcriptional
Response to Lung-Targeting Lipid
Nanoparticles in Vivo
por: Radmand, Afsane, et al.
Publicado: (2023) -
Increased PIP3 activity blocks nanoparticle mRNA delivery
por: Paunovska, Kalina, et al.
Publicado: (2020) -
4-Nitrophenol–piperazine (2/1)
por: Nagapandiselvi, Perumal, et al.
Publicado: (2013) -
Drug delivery systems for RNA therapeutics
por: Paunovska, Kalina, et al.
Publicado: (2022)